AXA Investment Managers’s Regeneron Pharmaceuticals REGN Stock Holding History

AXA Investment Managers’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	$35M	Buy	+62,291	New	+$35.2M	0.09%	189

Other funds holding REGN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AXA Investment Managers's REGN Position: Q3 2025 in Review

AXA Investment Managers opened a new position in Regeneron Pharmaceuticals (REGN) in Q3 2025: 62,291 shares worth $35M. The stake represents 0.09% of the portfolio and ranks #189 among its holdings.

1,244 funds tracked by Wall St. Rank hold REGN as of Q3 2025.

AXA Investment Managers held 62,291 shares of Regeneron Pharmaceuticals worth $35M as of Q3 2025.
Regeneron Pharmaceuticals was a new AXA Investment Managers position in Q3 2025.
Regeneron Pharmaceuticals made up 0.09% of AXA Investment Managers's portfolio in Q3 2025, its #189 holding.
1,244 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2025.

Based on AXA Investment Managers's 13F filing for Q3 2025, filed 14 Nov 2025.